<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Preventive action of new <z:chebi fb="11" ids="22586">antioxidant</z:chebi> SkQ1 has been studied in rats on model of <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo> caused by <z:chebi fb="2" ids="28918">epinephrine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The SkQ1 substance was given in dosages from 0.02 up to 20 moles/kg per os 2 weeks prior to experiment </plain></SENT>
<SENT sid="2" pm="."><plain>Intravenous bolus introduction of <z:chebi fb="2" ids="28918">epinephrine</z:chebi> (10 or 6 mkg/kg in different experimental series) caused an immediate rise of arterial pressure in average by 19% and decrease in heart rate in average by 44% </plain></SENT>
<SENT sid="3" pm="."><plain>The degree of changes of these parameters was approximately identical in <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0011675'>Arrhythmia</z:hpo> in the form of ventricular extrasystolia arose in the first 5 min </plain></SENT>
<SENT sid="5" pm="."><plain>The total number of <z:mp ids='MP_0009732'>extrasystoles</z:mp>, and index of <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> intensity have been 2-3 times lower in rats receiding SkQ1 in doses of 0.5, 2 and 20 moles/kg </plain></SENT>
<SENT sid="6" pm="."><plain>It was combined with increased survival rate of animals </plain></SENT>
<SENT sid="7" pm="."><plain>Smaller dosages of SkQ1 (0.02-0.1 moles/kg) were ineffective </plain></SENT>
<SENT sid="8" pm="."><plain>Results have shown that administration of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> <z:chebi fb="11" ids="22586">antioxidant</z:chebi> SkQ1 raises stability of the myocardium to arrhythmogenic action of <z:chebi fb="2" ids="28918">epinephrine</z:chebi> </plain></SENT>
</text></document>